Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
  • G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
  • G01S15/88—Sonar systems specially adapted for specific applications
  • G01S15/89—Sonar systems specially adapted for specific applications for mapping or imaging
  • G01S15/8906—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques
  • G01S15/8909—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques using a static transducer configuration
  • G01S15/8929—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques using a static transducer configuration using a three-dimensional transducer configuration
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
  • G01S7/00—Details of systems according to groups G01S13/00, G01S15/00, G01S17/00
  • G01S7/52—Details of systems according to groups G01S13/00, G01S15/00, G01S17/00 of systems according to group G01S15/00
  • G01S7/52017—Details of systems according to groups G01S13/00, G01S15/00, G01S17/00 of systems according to group G01S15/00 particularly adapted to short-range imaging
  • G01S7/52046—Techniques for image enhancement involving transmitter or receiver
  • G01S7/52047—Techniques for image enhancement involving transmitter or receiver for elimination of side lobes or of grating lobes; for increasing resolving power

Definitions

• the present invention relates to transcutaneous pharmaceutical compositions of hydroalcoholic type with an amount of alcohol greater than 30% containing a steroid hormone.
• the formulation of the topical compositions applied to the skin involves taking into account the site of action that the active ingredient must reach in order to exercise its therapeutic activity. Depending on the degree of penetration of the molecule across the cutaneous barrier, it is possible to distinguish:
• transdermal systems For the latter, the topical compositions are described as transdermal systems.
• the galenic forms used most frequently are matrix patches or reservoirs or gels. They have the essential advantage of avoiding the degradation reactions that occur in the gastrointestinal tract or during the first passage through the liver in the case of oral administration.
• the development of transdermal patches began in the 1970s leading to the approval of the first patch by the FDA in 1979. It delivered scopolamine to treat motion sickness. This development has continued and now the marketed patches contain active ingredients such as: fentanyl, lidocaine, nicotine, nitroglycerin, estradiol, testosterone, etc.
• the patches certainly have advantages in particular in terms of accuracy of the delivered dose but also a certain number of drawbacks identified today: > skin irritation,
• the gels have real advantages with regard to their cutaneous tolerance, their cosmetic appearance, their ease of preparation, their low industrial cost and the fact that they offer possibilities of content of active ingredient, in particular. solvent and more penetrating agent due to a hydroalcoholic base.
• permeability of the skin is great. This permeability is a function of several factors and depends on the intrinsic characteristics of the active ingredient (Kp, Mw, etc.) and those of the excipients of the composition.
• the penetrating agents are divided into several classes including, for example, fatty acids (eg oleic acid), terpenes (eg limonene), surfactants (eg polysorbates) or are still represented by new chemical entities. (ex: lauracapram or Azone).
• fatty acids eg oleic acid
• terpenes eg limonene
• surfactants eg polysorbates
• lauracapram or Azone A recent US publication, Ingo Alberti, Arnaud Grenier, Holger Kraus & Dario Norberto Carrara - Expert Opin. Drug Delivery (2005) 2 (5) p935 -950) analyzes the booming market for transdermal gels.
• Transdermal gels are at the origin of many patents or published works. They are often hydroalcoholic in nature with C 1 -C 4 short chain alcohols and use mainly as gelling agents polyacrylic acid derivatives such as carbomers or cellulose derivatives such as cellulose ethers or gums such as gum arabic or derivatives of polyvinylpyrrolidone or copolymers of polyoxyethylene and polyoxypropylene (see WO2006 / 125642 of ANTARES PHARMA). Their composition contains various penetration agents (see WO2002 / 17926 from BESINS ISCOVESCO Laboratories and UNIMED PHARMACEUTICALS and WO2002 / 11768 by ANTARES PHARMA).
• compositions of the prior art are therefore hydro-alcoholic monophasic transcutaneous pharmaceutical compositions with a quantity of alcohol greater than 30% containing a steroid hormone associated with at least one fatty acid ester and propylene glycol as a treatment agent. penetration.
• the hydroalcoholic phase is constituted by a mixture of water and C 1 -C 4 short chain alcohols and more specifically by a mixture of water and ethyl or isopropyl alcohol in proportions ranging from 80/20 to 20 / 80 (m / m), preferably in a range of 70/30 to 30/70.
• the amount of alcohol present in the hydroalcoholic phase is greater than 30%. Indeed, a quantity of alcohol greater than 30% allows a good solubilization of steroid hormones.
• These novel topical pharmaceutical compositions may further contain a soluble apolar solvent such as N, N-di-ethyl-m-toluamide or DEET in the hydroalcoholic phase, with a concentration ranging from 0.5% to 10% (m / m).
• these apolar solvents are represented by N, N-di-ethyl-m-toluamide or DEET.
• compositions are more specifically gels or hydroalcoholic solutions with an amount of alcohol greater than 30%. They make it possible to administer, in a controlled manner, solubilized steroid hormones such as, by way of nonlimiting examples, testosterone, estradiol, progesterone or their derivatives, by transcutaneous route, with a systemic aim.
• solubilized steroid hormones such as, by way of nonlimiting examples, testosterone, estradiol, progesterone or their derivatives
• transcutaneous route with a systemic aim.
• the composition according to the present invention may comprise at least gelling agent conventionally used in the pharmaceutical industry such as carbomer for example.
• the composition contains at least one fatty acid and propylene glycol ester as penetration agent with a concentration ranging from 0.5% to 10% (m / m) of the composition.
• the composition contains 2.5% (m / m) of propylene glycol monolaurate. According to another characteristic of the invention, the composition contains 5% (m / m) of propylene glycol monocaprylate.
• the composition contains a mixture, preferably equiponderal, of propylene glycol monolaurate and propylene glycol monocaprylate.
• the compositions according to the present invention may be in any form suitable for topical application such as, for example, a solution, a spray or even used in a transdermal device of the patch-tank type.
• the compositions according to the present invention may comprise any dermatologically acceptable excipient such as texturants, dyes, flavors or perfume, or even one or more emollients for counterbalancing the drying effect of the alcoholic component.
• emollients may be chosen from glycerol or propylene glycol.
• the steroid hormone concentration of these gels or solutions ranges from 0.1% to 5% (w / w) of the composition.
• the concentration of penetrating agent of the fatty acid ester and glycol or terpene derivative type ranges from 0.5% to 10% (w / w) of the composition.
• BESINS laboratories market ANDROGEL® a hydroalcoholic gel [alcoholic degree close to 71% (m / m)], dosed at 1% (m / m) in testosterone, the composition of which includes, in addition to water and ethanol 0.5% (w / w) of isopropyl myristate as penetrating agent and carbomer as gelling agent.
• Hydroalcoholic gels [alcoholic degree: 71% (w / w)] were prepared, based on carbomer, with 1% (w / w) testosterone, incorporating increasing amounts of propylene glycol monolaurate (PGML): 0.5 %, 1% and 2.5% (w / w) of propylene glycol monocaprylate (PGMC): 1%, 2.5% and 5% (w / w) or the mixture 2.5% (w / w) DEET + 2.5% (w / w) PGML or 2.5% (w / w) of levomenthol.
• PGML propylene glycol monolaurate
• PGMC propylene glycol monocaprylate
• the formulas are shown in the table below
• novel transcutaneous pharmaceutical compositions which are the subject of the invention are prepared according to a manufacturing process involving dispersion, dissolution and mixing steps, which are well known to those skilled in the art.
• the manufacturing process is exemplified below, for the preparation of 100 g of gel containing 2.5% (w / w) PGML.
• mice dorsal skin of "naked swiss" mice, volume of the cell: 22.5 ml,
• compositions according to the present invention it is possible to modulate the profile of the transcutaneous passage of testosterone by varying the quality and quantity of the penetration agent of the fatty acid ester and glycol type incorporated into the gel. alcoholic. This possibility makes it possible to adapt a gel dosage form or hydroalcoholic solution to a given therapeutic activity (notion of transcutaneous chronotherapy) since it is possible to obtain either a peak effect or, more interestingly, a passage with linear kinetics.
• the rapid absorption in the first hours of testosterone is followed by a flow that either decreases or is maintained at a value close to 10 ⁇ g / cm 2 / h in the best case.
• This is perfectly controlled by increasing the propylene glycol monolaurate or monocaprylate content, but also by incorporating a combination such as DEET + propylene glycol monolaurate [2.5% + 2.5% (m / m)] where we can linearize the flow over 24 hours which is remarkable and totally unexpected.
• transcutaneous hydroalcoholic pharmaceutical compositions of the invention may also contain other ingredients customary for this type of formulation such as: emollients (glycerol, propylene glycol), preservatives (antimicrobials) and antioxidants), dyes, perfumes, etc. contributing to give cosmetic qualities to said preparation.
• compositions according to the present invention are intended for topical application in the context of hormone replacement therapy for both men and women.
• the compositions of the present invention are particularly suitable for hormone replacement therapy in women for testosterone supplementation in women with menopausal-related disorders. Indeed, compared to patches transdermal devices, the compositions according to the present invention are particularly suitable for administering a small amount of testosterone on a small skin surface.
• the use of a topical gel or spray composition has a comfort of use and a significant aesthetic advantage for patients.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Physics & Mathematics (AREA)
• Remote Sensing (AREA)
• Radar, Positioning & Navigation (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Acoustics & Sound (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Physics & Mathematics (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Computer Networks & Wireless Communication (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39493869

Family Applications (1)

Country Status (11)

Families Citing this family (18)

Family Cites Families (13)

• 2007
  • 2007-12-14 FR FR0759864A patent/FR2924942B1/fr not_active Expired - Fee Related
• 2008
  • 2008-12-04 EP EP08862840A patent/EP2231115A1/fr not_active Withdrawn
  • 2008-12-04 AU AU2008337731A patent/AU2008337731A1/en not_active Abandoned
  • 2008-12-04 CN CN200880125929XA patent/CN101932305A/zh active Pending
  • 2008-12-04 CA CA2711961A patent/CA2711961A1/fr not_active Abandoned
  • 2008-12-04 KR KR1020107015043A patent/KR20100093589A/ko not_active Application Discontinuation
  • 2008-12-04 RU RU2010128471/15A patent/RU2010128471A/ru not_active Application Discontinuation
  • 2008-12-04 NZ NZ586759A patent/NZ586759A/xx not_active IP Right Cessation
  • 2008-12-04 WO PCT/EP2008/066808 patent/WO2009077345A1/fr active Application Filing
  • 2008-12-04 US US12/812,727 patent/US20100292199A1/en not_active Abandoned
• 2010
  • 2010-07-13 ZA ZA2010/04921A patent/ZA201004921B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events